CF101: Clinical Trials

10 trials of CF101, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 withdrawn. 10 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 8, Withdrawn 2
Phase 31Completed 1

Follow CF101: new trials by email Literature Review of CF101 trials Research Report on CF101

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Piclidenoson for Treatment of COVID-19
Piclidenoson, Placebo - COVID-19, Coronavirus Infection
Phase 2CompletedCan-Fite BioPharma62021-01-062022-04-22
Safety &Efficacy of CF101 to Subjects With Uveitis
CF101, Placebo - Uveitis, Posterior, Uveitis, Intermediate
Phase 2WithdrawnCan-Fite BioPharma2019-01-012018-02-01
A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee
CF101, Placebo - Osteoarthritis of the Knee
Phase 2WithdrawnCan-Fite BioPharma2018-11-012018-02-01
Trial of CF101 to Treat Patients With Psoriasis
CF101, Placebo - Plaque Psoriasis
Phase 2 / Phase 3CompletedCan-Fite BioPharma2932011-07-012020-11-18
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
CF101, Placebo control - Rheumatoid Arthritis
Phase 2CompletedCan-Fite BioPharma792010-10-012022-05-24
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
CF101, Placebo for - Ocular Hypertension, Glaucoma
Phase 2CompletedCan-Fite BioPharma892010-10-012022-05-12
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
CF101, Placebo - Rheumatoid Arthritis
Phase 2CompletedCan-Fite BioPharma2532008-02-012018-03-29
Safety and Efficacy Study of CF101 to Treat Psoriasis
CF101 1mg, CF101 2mg, CF101 4mg - Plaque Psoriasis
Phase 2CompletedCan-Fite BioPharma762007-06-012023-02-08
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
CF101, Placebo - Keratoconjunctivitis Sicca
Phase 2CompletedCan-Fite BioPharma802007-01-012022-05-09
Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
CF101 - Rheumatoid Arthritis
Phase 2CompletedCan-Fite BioPharma2542006-06-012023-09-18

Conditions studied

Arthritis, Rheumatoid (3)  ·  Psoriasis (2)  ·  COVID-19 (1)  ·  Coronavirus Infections (1)  ·  Dry Eye Syndromes (1)  ·  Glaucoma (1)  ·  Keratoconjunctivitis Sicca (1)  ·  Ocular Hypertension (1)  ·  Osteoarthritis (1)  ·  Osteoarthritis, Knee (1)  ·  Uveitis (1)  ·  Uveitis, Intermediate (1)  ·  Uveitis, Posterior (1)

Sponsors

Can-Fite BioPharma (10)

Countries

Israel (10)  ·  Bulgaria (6)  ·  Romania (3)  ·  Poland (2)  ·  Serbia (2)  ·  Ukraine (2)  ·  United States (2)  ·  Czechia (1)

Top investigators

Michael H Silverman, MD (6)  ·  Irit Bareket, MD (1)  ·  Michael David, MD (1)  ·  Zivit Harpaz (1)

Results publications

PMID 20304499, PMID 21504485